scholarly journals Comparison of Prognosis according to Tumor Size in Small Breast Cancer with Lymph Node Involvement

2016 ◽  
Vol 4 (2) ◽  
pp. 48-57
Author(s):  
Hong Seok Han ◽  
Jai Min Ryu ◽  
Isaac Kim ◽  
Hyun-June Paik ◽  
Sungmin Park ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Tumor Size ◽  
Lymph Node Involvement ◽  
Small Breast ◽  
Node Involvement ◽  
Small Breast Cancer

scholarly journals Comparison of ER, PR, Ki67 and HER-2/neu Reactivity Pattern with Patients’ Age, Histologic Grade, Tumor Size and Lymph Node Status in Invasive Ductal Breast Cancer

2020 ◽  
Vol 13 (6) ◽  
Author(s):  
Mahsa Ahadi ◽  
Motahareh Heibatollahi ◽  
Sara Zahedifard
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Tumor Size ◽  
Histological Grade ◽  
Lymph Node Involvement ◽  
Lymph Node Status ◽  
Invasive Ductal Breast Cancer ◽  
Ductal Breast Cancer ◽  
Node Involvement ◽  
Her 2

Background: Breast cancer is the most prevalent neoplasm diagnosed in Iranian women. Objectives: The current study was performed to measure the hormone receptor status and its possible connection with the patient’s age, tumor size, histological grade, and lymph node status and involvement in patients with invasive ductal breast cancer (IDBC) Methods: A total of 103 women with IDBC recently diagnosed at the Department of Pathology of Shohada-E-Tajrish Hospital were entered into this study. The mean age of the patients was 48.4 years, and 59.2% of cases were 50 years old or less. Results: Most lesions (78.6%) were more than 2 cm at their greatest dimension. Grade-II lesions were observed in a large number of patients and 59.8% of cases had lymph node involvement. Positive ER, PR, and HER-2/neu were detected in 59%, 57%, and 29% of patients, respectively. A significant correlation was found between patients’ age and histologic score, tumor dimension and both histologic score and nuclear grade, and, finally, between lymph node involvement and nuclear grade. Conclusions: According to previous studies, the evaluation of hormone receptor status in patients with breast cancer is strongly recommended. Here, by studying its possible connection with the patient’s age, tumor size, histological grade, and lymph node metastasis, we detected some biomarkers, which could be used as prognostic indices in these patients. These biomarkers could help us in the clinical management of patients with IDBC by providing the best therapeutic options.

Nomogram to predict sentinel lymph node involvement in patients with clinically node-negative breast cancer receiving neoadjuvant chemotherapy.

2012 ◽  
Vol 30 (27_suppl) ◽  
pp. 150-150 ◽  
Author(s):  
Lisa R. Allen ◽  
Pranjali V. Gadgil ◽  
Roland Bassett ◽  
Kelly Hunt ◽  
Elizabeth Ann Mittendorf ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Neoadjuvant Chemotherapy ◽  
Tumor Size ◽  
Multidisciplinary Treatment ◽  
Tumor Location ◽  
Lymph Node Involvement ◽  
Breast Cancer Patients ◽  
Node Negative ◽  
Node Involvement

150 Background: Sentinel lymph node biopsy (SLNB) has been shown to be an accurate predictor of axillary lymph node involvement in breast cancer patients treated with neoadjuvant chemotherapy (NAC). A predictive model of SLN positivity in clinically node negative patients who completed NAC can assist in preoperative multidisciplinary treatment decision making, such as planning for postmastectomy radiation therapy and breast reconstruction. Methods: We reviewed our prospective database to identifyclinically node negative patients with invasive breast cancer who underwent NAC and SLNB from 1998-2011. Clincopathologic factors including age, tumor location, histology, nuclear grade, tumor size, decrease in tumor size with therapy, multifocality, nodal appearance on preoperative ultrasound, hormone receptor status, and lymphovascular invasion (LVI) were analyzed. A nomogram to predict SLN metastasis was developed using multivariate logistic regression analysis. Results: A total of 836 patients were treated with NAC followed by SLNB. Of these, 160 patients (19.1%) had a positive SLN. All factors were significant predictors of SLN positivity on univariate analysis except tumor location and nodal appearance on preoperative ultrasound. Multivariate analysis showed that young age, invasive lobular histology, tumor size, multifocality, and LVI were independent positive predictors of SLN positivity whereas high grade, response to chemotherapy, and triple negative hormone receptor status were negative predictors. Favorable histologies were strongly associated with a lower rate of SLN positivity but were excluded from the nomogram due to small numbers of patients (N=14). Discrimination of the nomogram to correctly predict SLN positivity was measured using the area under the receiver operating characteristic curve (AUC). The unadjusted AUC was 75.9, while the internally validated 2000 bootstrap sample-adjusted AUC was 74.2. Conclusions: Neoadjuvant chemotherapy is known to decrease the incidence of positive nodes in breast cancer patients. Use of our nomogram preoperatively can assist in decisions regarding multidisciplinary treatment planning.

Male breast carcinoma in United States: Survival rate and determinants of prognosis.

2011 ◽  
Vol 29 (27_suppl) ◽  
pp. 32-32
Author(s):  
S. Talluri ◽  
R. Kakarala ◽  
T. Karedan ◽  
M. Kakarala
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Median Survival ◽  
Male Breast Cancer ◽  
Tumor Size ◽  
Lymph Node Involvement ◽  
Female Breast Cancer ◽  
Male Breast ◽  
Female Breast ◽  
Node Involvement

32 Background: Male breast cancer (MBC) is rare and accounts for less than 1% of all cancers in men. It causes significant morbidity and mortality due to late diagnosis. The primary objective of our study is to update information about the receptor status, pathology, survival rates, and prognostic factors for MBC. Our secondary objective is to determine racial differences in survival of MBC and compare tumor characteristics with female breast cancer (FBC) patients. Methods: We analyzed a retrospective cohort of breast cancer patients included in National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) from 1990 to 2007. Differences between patient and disease characteristics at the time of diagnosis among MBC and FBC patients were compared using chi-square test. Overall survival was estimated using Kaplan-Meier method. Cox proportional hazards regression model was used to determine the independent variables that affect survival. Results: We included 2,475 men and 393,259 women with breast cancer in our analysis. Median age at diagnosis was higher in men compared to women (67 vs 61years). Men had more frequent lymph node involvement (32% vs. 22%), ER positivity (66% vs. 57%) and PR positivity (57% vs. 49%) breast cancer than women (P<0.001). Overall median survival in MBC was 9 years, 5-year survival was 63% and 10-year survival was 43%. Increased age, larger tumor size, higher grade, lymph node involvement, ER and PR negative status were significantly associated with decreased survival in univariate analysis (P <0.05). In multivariate analysis, age > 65 years at the time of diagnosis, larger tumor size, positive lymph node status, ER negative status and poorly differentiated grade were associated with decreased survival (P <0.02). However PR status was not a significant predictor of survival. The median survival in African American males was lower as compared to Caucasians (7.08 vs. 9.2 yrs.) (P=0.02). Conclusions: Male breast cancer differs from female breast cancer in important biological characteristics with a higher age at diagnosis and frequent lymph node involvement. Age greater than 65 years, tumor size, grade, lymph node involvement and ER status of the tumor are independent predictors of survival in MBC.

Clinical and pathological comparison of patients with breast cancer under age 35 with those over age 70.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e11045-e11045
Author(s):  
Pinar Dal ◽  
Samed Rahatli ◽  
Nadire Kucukoztas ◽  
Selim Yalcin ◽  
Omer Dizdar ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Tumor Size ◽  
Metastatic Lymph Node ◽  
Lymph Node Involvement ◽  
Axillary Lymph ◽  
Age Group ◽  
Node Involvement ◽  
Young Breast Cancer

e11045 Background: Despite intensive treatment given to young breast cancer women, prognosis is stil poor in this group of population. However, older patients seem to have better prognosis. Methods: We performed the retrospective study for 50 women ≤35 yo compared with 50 women ≥70 yo, diagnosed and treated from 1991-2009 at Baskent University Hospitals. Results: Older women were more likely to have lower tumor grades and higher HR positivity, ≤35 years old women were more likely to have Her2 positivity, larger tumor size and metastatic lymph node involvement. Median follow up duration was 21.7 (2-91) months for ≤35 group, whereas it was 36.2 (4-195) months for ≥70 years group. Recurrence was observed in 34% of the young age group and 24% of the older age group. Three patients from the young group and 4 patients for ≥70 years age group died during the follow-up Young breast cancer patients have poor prognosis. Even after adjustment of the data, Overall survival and relapse free survival showed worse prognosis. Normal prognostic factors like tumor size, axillary lymph node involvement and grading can therefore be not the explanation for the more agressive disease progression alone. Older women were more likely to have lower tumor grades and higher hormone receptor positivity, ≤35 years old women were more likely to have Her2 positivity, larger tumor size and metastatic lymph node involvement. Median follow up duration was 21.7 (2-91) months for ≤35 age group, whereas it was 36.2 (4-195) months for ≥70 years group. Recurrence was observed in 34% of the young age group and 24% of the older age group. Three patients from the young group and 4 patients for ≥70 years age group died during the follow-up Young breast cancer patients have poor prognosis. Even after adjustment of the data, Overall survival and relapse free survival showed worse prognosis. Normal prognostic factors like tumor size, axillary lymph node involvement and grading can therefore be not the explanation for the more agressive disease progression alone. Conclusions: There are various reasons such as difficulty in diagnosing the patients the patients at earlier stage because of the higher density of breast tissue at younger age may be one of the reason.

scholarly journals A Study on the Relationship Between Tumor Size, Tumor Grade and Lymph Node Involvement in Canine Mammary Cancer: Simulation of Tumor Behavior in Human Breast Cancer

2021 ◽  
Author(s):  
Sanaz Rismanchi ◽  
Pejman Mortazavi ◽  
Samad Muhammadnejad
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Tumor Size ◽  
Mammary Cancer ◽  
Tumor Grade ◽  
Lymph Node Involvement ◽  
Lymph Node Status ◽  
Comparative Oncology ◽  
Canine Mammary Cancer ◽  
Node Involvement

Background: In the last two decades, canine mammary cancer has played an essential role in human breast cancer research. There are various similarities between biological and clinical features of canine breast cancer and female breast cancer in many cases. Clinical studies and evaluation of prognostic factors in canine mammary cancer can increase reliability in generalizing results to human cancers. This study was performed in the direction of comparative oncology. Methods: We collected clinicopathological data of an invasive type of canine mammary carcinoma from clinical records and pathology reports. Age, tumor laterality, tumor size, lymph node status, and tumor grade were recorded, and the relationships between the parameters were evaluated using linear regression analysis. Results: Ninety-seven patients were included in the study, and the mean age was 10.06 ± 2.73 years. The left mammary gland was involved in 51% of cases, and pT2 was the most common tumor size. Lymph nodes were involved in 27% of patients, and 43% of tumors were grade I. Statistical analysis showed no relationship between tumor size and laterality with other clinicopathological features. However, there was a statistically significant relationship between tumor size and tumor grade, and lymph node status. As the tumor size increased, tumor grade and the risk of lymph node involvement raised. Conclusion: Similar results of this study to breast cancer in women show that canine mammary carcinoma is a suitable model in comparative oncology research. Dogs live shorter than humans so that researchers can get the results of treatment and perform survival rate assessments faster in clinical trials. By considering ethical principles, dogs with breast cancer may replace phases I and II of human clinical trials in some cancer types soon.

Risk factors of brain metastasis in a series of Egyptian breast cancer patients: A single-institution experience.

2011 ◽  
Vol 29 (27_suppl) ◽  
pp. 50-50
Author(s):  
H. A. Azim ◽  
R. A. Malek ◽  
D. Abdelmonem ◽  
S. Amin ◽  
M. Abdelsalam
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Brain Metastasis ◽  
Cancer Patients ◽  
Tumor Size ◽  
Lymph Node Involvement ◽  
Breast Cancer Patients ◽  
Over Expression ◽  
Node Involvement

50 Background: Incidence of cerebral metastasis is increasing among breast cancer patients. Many factors have been reported associated with increased risk of brain metastasis. The aim of this retrospective analysis is to investigate the predictive factors for the development of brain metastasis in breast cancer patients. Methods: We retrospectively analyzed histologically proven breast cancer patients who presented to Cairo Oncology Center (COC) in the period from 1999 till 2008, with follow up period of 6 months at least for those in adjuvant setting. The following factors were analyzed: age, tumor size and grade, nodal status, ER, PgR and HER2 over-expression status. Results: Our study included 2,338 patients. 96 patients (4.1%) experienced brain metastasis during the course of their disease. 3 patients had brain metastasis among other sites of distant spread at first presentation to COC. 30 out of 96 patients (31.25%) with localized breast cancer had brain metastasis at first relapse with 13 (13.5%) of them had isolated brain metastasis. In a median follow-up of 37.1 months (6-277) the median time to develop brain metastasis was 26.5 months (0-144). Based on univariate analysis, the following variables were associated with shorter time to develop brain metastasis: tumor size more than 5 cm (HR = 2.1, 95% CI 1.14-3.87), lymph node involvement at diagnosis (HR = 1.57, 95%CI 1.17-2.10), ER negativity (HR = 1.58, 95%CI 1.33-1.73), PgR negativity (HR = 1.55, 95%CI 1.29-1.72) and HER2-neu over-expression (HR = 2.68, 95%CI 1.51-4.75). On multivariate analysis, only patients with lymph node involvement at diagnosis and those with HER2-neu positive breast cancer were associated with shorter time to develop brain metastasis. Conclusions: We concluded that HER2 over-expression as well as lymph node involvement are the 2 main factors associated with shorter time to develop brain metastasis. These patients could be good candidates for trials investigating the role of any prophylactic intervention to decrease their risk to develop brain metastases.

EGF-R and steroid receptors in breast cancer: A comparison with tumor grading, tumor size, lymph node involvement, and age

1993 ◽  
Vol 26 (3) ◽  
pp. 221-227 ◽  
Author(s):  
R. Zeillinger ◽  
F. Kury ◽  
P. Speiser ◽  
G. Sliutz ◽  
K. Czerwenka ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Tumor Size ◽  
Steroid Receptors ◽  
Lymph Node Involvement ◽  
Tumor Grading ◽  
Node Involvement
Sign in / Sign up

Export Citation Format

Share Document